February 7, 2018
Published study reports use of nutritional ketosis with mobile app intervention could reverse Type 2 diabetes
SAN FRANCISCO and WEST LAFAYETTE, Ind. – A newly published study has shown that an individualized approach to nutritional ketosis (utilizing fat rather than glucose to fuel the body), combined with remote monitoring via a mobile application, could sustainably and safely reverse Type 2 diabetes.
The study, compiled by San Francisco-based Virta Health, reports that the treatment could also improve other chronic metabolic diseases without medication or surgery intervention.
Purdue University in West Lafayette, Indiana, IU Health Arnett in Lafayette, Indiana, and others collaborated with Virta Health to publish one-year outcomes from the ongoing 5-year trial Wednesday Feb. 7 in Diabetes Therapy. Other collaborators include the University of Southern California, Keck School of Medicine, Los Angeles; Washington University School of Medicine, Department of Genetics, St. Louis, Missouri; and Ohio State University, Department of Human Sciences, Columbus, Ohio.
The study, “Effectiveness and Safety of a Novel Care Model for Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study,” oversaw 349 Type 2 diabetes patients. A control of 87 patients elected to receive “usual care” provided by their own physicians and dieticians following the American Diabetes Association recommendations. The other 262 patients elected to adopt individualized, low carbohydrate, high fat nutrition while being connected to a health coach and physician via a mobile application, which also contained educational resources.
The intervention studied focused on five points: access to a health coach, a physician for medication management, biomarker feedback, nutrition and behavior change education, and an online community.
“We feel that it is really important to support a patient in many different ways,” said the study’s principal investigator, Dr. Sarah Hallberg. “Making lifestyle changes can be hard, but the ability to ask questions whenever necessary provided patients with a support system to stay on a potentially life-changing program.”
The dietary intervention promoted non-starchy carbohydrate sources with a moderate protein intake. This model enabled patients to sustain nutritional ketosis, where the body uses fat as its primary fuel source instead of glucose. Additionally, patients interacted with their health coach or physician via the mobile application, sometimes multiple times per day.
“Due to the unique structure of the trial and use of telemedicine, we helped prevent any significant hypoglycemic events,” Hallberg said. “Instead of patients scheduling an office visit, they could log their blood sugar and ketone levels in the app. Then, both the patient and I could track their levels and make adjustments accordingly.”
Virta Health and colleagues reported the results of the first year of the trial. Of the study’s 262 intervention patients, 83 percent remained in the program. The patients also exhibited an average decrease of 1.3% in hemoglobin A1C (a marker that represents a person’s average blood glucose over the last 3 months). Additionally, patients saw 12 percent weight loss during the year.
The findings demonstrated a reversal in diabetes progression. For example, of those receiving the Virta Treatment, 94 percent of patients on insulin decreased or eliminated their dosage by year’s end, and 60 percent of patients showed hemoglobin A1C levels below the diabetes threshold without medication or only metformin (metformin has indications outside of T2D). In contrast, usual care participants experienced no significant changes in A1C or diabetes medication use.
“Our results push against the accepted norm that A1C cannot be improved while taking patients off of medication,” Hallberg said. “Our trial shows we did both—sometimes in a matter of weeks—and sustained and even improved results at one year. Establishing the right intervention and remote support resources is critical for our treatment approach.”
CEO Sami Inkinen, and Drs. Stephen Phinney and Jeff Volek co-founded Virta Health in 2014 to address Type 2 diabetes, which affects hundreds of millions of people globally and creates nearly $300 billion of economic impact in the United States alone.
“We have worked long and hard to establish an evidence-based treatment to reverse, not manage, type 2 diabetes to change the course of the epidemic and help patients achieve better health.” Inkinen said. “We are committed to the success of each one of our patients and continually improving our approach in order to reach our goal of reversing type 2 diabetes in 100 million people by 2025."
Virta Health has opened an office in the Purdue Research Park of West Lafayette that will be led by Hallberg. Any individual with Type 2 diabetes or pre-diabetes can sign up for the Virta Treatment. Visit www.virtahealth.com for more information.
Writer: Kelsey Henry, 765-588-3342, firstname.lastname@example.org
Purdue Research Foundation Contact: Cynthia Sequin, 765-558-3340, email@example.com
Sources: Sarah Hallberg, firstname.lastname@example.org
Paul Sytsma, email@example.com
Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study
Sarah J. Hallberg, Amy L. McKenzie, Paul Williams, Nasir H. Bhanpuri, Anne L. Peters, Wayne W. Campbell, Tamara Hazbun, Brittanie M. Volk, James P. McCarter, Stephen D. Phinney, Jeff S. Volek
*Indiana University Health Arnett, Medically Supervised Weight Loss, Lafayette, Indiana; Virta Health, San Francisco, California; Independent Consultant, Lafayette, California; University of Southern California, Keck School of Medicine, Los Angeles, California; Purdue University, Department of Nutrition Science, West Lafayette, Indiana; Washington University School of Medicine, Department of Genetics, St. Louis, Missouri; The Ohio State University, Department of Human Sciences, Columbus, Ohio
Carbohydrate restriction markedly improves glycemic control in patients with Type 2 diabetes (T2D) but necessitates prompt medication changes. Therefore, we assessed the effectiveness and safety of a novel care model providing continuous remote care with medication management based on biometric feedback combined with the metabolic approach of nutritional ketosis for T2D management. We conducted an open label, non-randomized, controlled, before-and-after 1-year study of this continuous care intervention (CCI) and usual care (UC). Primary outcomes were glycosylated hemoglobin (HbA1c), weight, and medication use. Secondary outcomes included fasting serum glucose and insulin, HOMA-IR, blood lipids and lipoproteins, liver and kidney function markers, and high sensitivity C-reactive protein (hsCRP). These results demonstrate that a novel metabolic and continuous remote care model can support adults with T2D to safely improve HbA1c, weight, and other biomarkers while reducing diabetes medication use.